Thursday, November 28
Mazagon Dock Shipbuilders on Tuesday reported a 75.7% YoY jump in its profit after tax (PAT) to Rs 585 crore for the quarter ended September 2024. The same stood at Rs 332.9 crore in the year-ago period.Revenue from operations for the period rose to Rs 2,756.8 crore, up from Rs 1,827.7 crore in the same quarter of the previous financial year, marking a 50.8% year-on-year (YoY) increase.The company's EBITDA surged 189.1% YoY to Rs 511 crore for the September quarter, compared to Rs 177 crore in the same quarter of the previous financial year.EBITDA margins increased by 886 basis points to 18.5% in the second quarter, up from 9.7% in the corresponding quarter of the previous financial year.More to come...
New Delhi: The alarming issue of exaggerated health claims associated with supplements will be under stricter scrutiny as a government panel proposes to shift it under the control of drug regulator instead of Foods Safety and Standards Authority of India (FSSAI). The expert panel was earlier formed to look into addressing the overlapping concerns between nutraceuticals and drugs.People in the know told ET that the panel has proposed that the claims related to cure or promise to mitigate disease disorder or condition including disease risk reduction (DRR) shall be regulated by the Central Drugs Standard Control Organisation (CDSCO). "The DRR claims or products having properties for treatment of a disease shall not be approved under FSS," said a source, sharing that a report has been sent to
